DIC

Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.

The FDA approval of BiDil for heart failure in African American patients has underscored the concept that two patients can respond differently to the same medication. This concept holds true for a wide variety of everyday medications, and in many cases is due to individual gen...

Appendicitis: Evolving Tools to Diagnose a Classic Disease

Contributing Editor Appendicitis is a common, potentially lethal condition that affects 7% of individuals sometime in their lives. The condition occurs when the appendix, a blind pouch of intestine at the proximal colon, becomes obstructed by mucus, stool, or lymphatic tissue. Infection ensues, which can rapidly evol...

AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

PORTLAND, Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPharma, Inc.(Nasdaq:AVII) announced today that its partner Cook Medical hascompleted target patient enrollment and released six-monthfollow-up data from a Phase II clinical trial known as Appraisal.The trial, currently being held in Germany, was designed to studythe effect of the Neugene(R) antisense drug Resten-MP(TM), whenused in conj...

Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting System's Success in Mouse Model Reported in Cancer Cell

HOUSTON, July 9, 2007 - A molecularly engineeredtherapy selectively embeds a gene in pancreatic cancer that shrinksor eradicates tumors, inhibits metastasis, and prolongs survivalwith virtually no toxicity, researchers from The University ofTexas M. D. Anderson Cancer Center report in the July 9 edition ofCancer Cell. "This vehicle, or vector, is so targeted and robust in itscanc...

New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

EXCLAIM is the First International Study to Show That ExtendedThromboprophylaxis Reduces VTE Risk in Acutely-ill Medical PatientsWith a Statistically Significant 44% PARIS, July 8, 2007 /PRNewswire-FirstCall/ --Sanofi-aventisannounced today the results of the EXCLAIM (EXtended CLinicalprophylaxis in Acutely Ill Medical patients) study, which showedthe benefit of extended prophylaxi...

TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment

LOD, Israel--(BUSINESS WIRE)--Jul 9, 2007 - TransPharma MedicalLtd., a specialty pharmaceutical company focused on the developmentand commercialization of drug products utilizing a proprietaryactive transdermal drug delivery technology, announced todaypromising results of its phase I clinical trials demonstrating thesafety and pharmacokinetic profile of its ViaDerm-hPTH (1-34)product for th...

Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology

LUGANO, Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOPHARMOncology, Inc. (NASDAQ: ZIOP) announces that positive interim datafrom an ongoing phase II trial of ZIO-201 (isophosphoramide mustard- IPM) to treat advanced sarcoma patients was presented at theEuropean Society of Medical Oncology (ESMO) meeting held July 5-8,2007 in Lugano, Switzerland. The abstract entitled, "Phase-I/IIStudy of...

Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer - LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- ResponseGenetics, Inc. today announced that positive Phase III clinicaldata published in the July 1 issue of the Journal of ClinicalOncology suggests that low expression of the biomarkerExcision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsieswith advanced non-...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today announced that an articlehas been published in the July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cancer using Proellex. The article reviews the findings froma study conducted in an accepted in vivo rat model of breastcancer. The study...

Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia

ROCHESTER, Minn., July 2, 2007-Women with at least three sites ofcellular atypia in breast tissue are nearly eight times more likelythan average women to develop breast cancer, according to findingsof a Mayo Clinic Cancer Center led study of women with atypicalhyperplasia. The findings are published in the July 1 issue of theJournal of Clinical Oncology. Several previous studies have show...

Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine

- Article Discussing Pharmacokinetics and Dose Proportionality ofCompany's Once-Daily Tramadol to be Published in BiopharmaceuticsJournal - LAVAL, QC, June 29, 2007 /PRNewswire-FirstCall/ - Labopharm Inc.today announced that it will present a poster discussing the dosetitration of its once-daily formulation of tramadol at the 3rdInternational Forum on Pain Medicine to be held June 28 to J...

European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGene's Cancer-Killing Virus in Press Conference

* Presentation of efficacy trends from ongoing phase I/II trialof oncolytic HSV * Poster selected by ESMO for presentation inpress conference MARTINSRIED, Germany, June 29, 2007.--The biotech companyMediGene AG (Frankfurt, Prime Standard: MDG) announces that a casereport from the ongoing clinical trial of MediGene's cancer killingvirus will be presented in a press conferen...

The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients

- Data Presented at the 11th International Myeloma Workshop - NORTH HOLLYWOOD, Calif., and KOS, Greece, June 29, 2007/PRNewswire/ -- The International Myeloma Foundation (IMF) --supporting research and providing education, advocacy and supportfor myeloma patients, families, researchers and physicians -- todaysaid that updated statistics reported at the 11th InternationalMyeloma Workshop i...

New Proof of Genistein's Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jun 27, 2007 - Annals ofInternal Medicine has published the results of a two-year clinicalstudy on the impact of genistein on bone loss. The paper, "Effectsof the Phytoestrogen Genistein on Bone Metabolism in OsteopenicPostmenopausal Women-A Randomized Trial," appears in the currentissue (June 19, 2007) and details the safety and efficacy ofgenistein for...

Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal

LIVINGSTON, N.J.--(BUSINESS WIRE)--Jun 25, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) announced today that an interimanalysis of a pregnancy study comparing the efficacy of CRINONE(R)8% (progesterone gel) to compounded intramuscular progesterone(IMP) injections is now available online and will be published inFertility and Sterility, the journal of the American Society forReproductive...

Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine

SAN FRANCISCO & NEW DELHI, India--(BUSINESS WIRE)--Jun 21, 2007- The Institute for OneWorld Health, a US-based non-profitpharmaceutical company, today announced that Phase 3 researchrelated to its first approved drug product, Paromomycin IMInjection (Paromomycin), was published in the current issue of TheNew England Journal of Medicine (NEJM). This clinical trial showsthat the medicine...

New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jun 21, 2007 - BioSantePharmaceuticals, Inc. (AMEX:BPA) today provided comment on theWomen's Health Initiative (WHI) Coronary Artery Calcium Studypublished yesterday in The New England Journal of Medicine (NEJM).The study found that younger menopausal women (aged 50-59) whoreceived a standard dose of estrogen therapy had significantly lesscoronary artery...

Next Safety, Inc.'s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery

WEST JEFFERSON, N.C.--(BUSINESS WIRE)--Jun 15, 2007 - Next Safety,Inc. has identified basic scientific mechanisms that promise torevolutionize pulmonary drug delivery. This proprietary technologyuses a stream of purified air to deliver medications deep into thepulmonary system. It is considered superior to other drug deliverysystems because it rapidly administers aerosolized drugs to thelin...

Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood

Preclinical Studies Show 227Th-rituximab More Effective atKilling CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab(Zevalin) OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), theNorwegian cancer therapeutics company, announces that a researchpaper showing the potential of its TH-1 technology for targetedcancer therapy has been published by the leading medical journal,...

Data Showing that ReGen's Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia

London, UK, June 11, 2007-ReGen is pleased to announce thata review of scientific and clinical information on Colostrinin, itsnutraceutical product which the Company believes has the potentialto support healthy cognitive function, was presented today at the2007 International Congress on Natural Medicine in SurfersParadise, Queensland, Australia by Dr Marian Kruzel, ReGen's ChiefScientifi...

Research Indicates Geron's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 11, 2007 - GeronCorporation (Nasdaq:GERN) today announced the presentation ofresearch studies indicating that GRNOPC1, the company's humanembryonic stem cell (hESC)-based therapeutic for the treatment ofspinal cord injury, evades a direct attack by the human immunesystem. Presented by Geron scientist Ross Okamura at the Federation ofClinical Immun...

ApoCell's Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy

HOUSTON--(BUSINESS WIRE)--Jun 7, 2007 - ApoCell, Inc. presented theresults of a study conducted by researchers at the University ofChicago and ApoCell at the 2007 annual meeting of the AmericanSociety of Clinical Oncology (ASCO) held in Chicago in early June.The study showed that ApoCell's advanced pharmacodynamic biomarkerassay technology provides reliable predictive data of clinicalrespon...

Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis

ECUBLENS, SWITZERLAND, June 07, 2007 /PRNewswire-FirstCall/ -Neurochem (International) Limited (Neurochem), a wholly-ownedsubsidiary of Neurochem Inc. , announces that the New EnglandJournal of Medicine (NEJM) published the results of the "EprodisateFor AA Amyloidosis Trial" (EFAAT), recognized as a landmarkclinical trial in the search for a treatment of AA amyloidosis. Theresults of the...

Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England

"The editorials published by the NEJM are disappointing andmisleading in that they disregarded important pieces of data thatare extremely relevant to patients and physicians. Mostsignificantly the editorials ignored data that showed no evidenceof any increase in cardiovascular death or death from anycause."...

Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedical's Electroporation DNA Delivery Technology

SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today that thecompany's partner, Vical Incorporated, presented positive interimsafety and tolerability data on 18 subjects from an ongoing Phase Iclinical trial...

Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today the companydelivered multiple presentations on preclinical study results andnew device innovations relating to its electroporation-mediated DNAdelivery te...

Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy

- Results Presented at Society of Nuclear Medicine Annual Meeting - WASHINGTON, June 05, 2007 /PRNewswire-FirstCall/ --Immunomedics, Inc. , a biopharmaceutical company focused ondeveloping monoclonal antibodies to treat cancer and other seriousdiseases, today announced that initial results from a Phase I studywith the Company's humanized anti-MUC1 monoclonal antibody (hPAM4),labeled with...

Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - JavelinPharmaceuticals, Inc. (AMEX: JAV), a leading developer of novelproducts for pain control, today announced that its Phase 2multi-dose study of Rylomine was published in Pain Medicine, theofficial journal of The American Academy of Pain Medicine. Thearticle, entitled, "Analgesic Efficacy and Safety ofMorphine-Chitosan Nasal Solution in P...

Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Introgen Therapeutics, Inc.(NASDAQ: INGN) and the Company's clinical collaborators todayreported updated Phase 2 data demonstrating a significantcorrelation between abnormal p53, tumor responses and increasedsurvival following ADVEXIN(R) therapy in patients with recurrentsquamous cell carcinoma of the head and neck. The data (Abstract#6057) were prese...

Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 4, 2007 - Molecular InsightPharmaceuticals, Inc. (NASDAQ: MIPI) announced today that thecompany will present the results of several preclinical studies atthe 54th annual meeting of the Society of Nuclear Medicine (SNM) inWashington, D.C. The presentations include data on Azedra(TM)(Ultratrace (131)I-MIBG), the company's clinical-stage, targetedradiothe...

World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester

Breakthrough in Research and Treatment of Rare but DevastatingCondition LONDON, June 1, 2007-Researchers at Queen Mary University Londonand the University of Leicester and have today (Friday June 1)announced a potential breakthrough in the treatment of a rare butdevastating medical condition that can affect children and youngpeople. In a world first, the clinicians and scien...

Medicure's MEND-CABG Trial Results Published in Peer Reviewed Journal

WINNIPEG, Manitoba - (May 31, 2007) Medicure Inc. (TSX:MPH;Amex:MCU), a cardiovascular focused biopharmaceutical company,today announced that the results from its Phase 2 MEND-CABG trialare featured in a peer reviewed article in the June edition of TheJournal of Thoracic and Cardiovascular Surgery, published by theAmerican Association of Thoracic Surgery. The article, titled, "Effects of...

Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD

SEATTLE--(BUSINESS WIRE)--May 29, 2007 - Mitopharm Corporation,Inc. (Pink Sheets:MTPM), releases the results of a research paperwhere Professor Dr. Robert Ko published the beneficial effects ofSchisandrin B, the precursor of (-) Schisandrin B - a noveldiscovery by Dr. Ko - on Ischemic Heart Disease. In a research paper entitled "SCHISANDRIN B PROTECTS AGAINSTMYOCARDIAL ISCHEMIA-REPERFUSIO...

Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings

AUSTIN, Texas--(BUSINESS WIRE)--May 29, 2007 - IntrogenTherapeutics, Inc. (NASDAQ:INGN) and the Company's clinicalcollaborators will report updated Phase 2 clinical trial resultsfor its lead cancer therapy product candidates at the upcomingannual meetings of The American Society of Clinical Oncology (ASCO)in Chicago and the American Society of Gene Therapy (ASGT) inSeattle. "We have a st...

Limiting Eligibility for Medical Studies Can Omit Women, African-Americans, Stanford Study Finds

STANFORD, Calif.--(BUSINESS WIRE)--May 24, 2007 - A new analysishas found that many alcohol treatment studies are designed in waysthat inadvertently omit women and African-Americans fromparticipation. The Stanford University School of Medicineresearcher who led the effort said the findings should remind allscientists that strict study eligibility criteria can haveunintended, negative conseq...

Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced today the positive results of studies of theinvestigational medication guanfacine extended release (GXR,previously referred to as SPD503), a selectivealpha-2A-adrenoceptor agonist. These data from two short-term phaseIII placebo-controlled studies and two long-term phase IIIopen-label studies, presented at the 2007 Amer...

Inovio Biomedical's DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results

SAN DIEGO--(BUSINESS WIRE)--May 24, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA-based DNAvaccines for cancers and infectious diseases and a novelalternative to surgery to treat localized cancers, announced todaythat interim clinical trial results demonstrated that a DNA-basedimmunotherapy delivered by Inovio's electroporation technology wassafe and tole...

New Data Focuses on Abuse of Stimulant Medication

New Data Suggests Less Abuse-Related Effects For OROS(r)Methylphenidate Two New Studies Highlight Potential Benefit of Unique OROS(r)Formulation SAN DIEGO, CA, May 22, 2007 - Stimulant drug abuse remains anongoing concern for parents and physicians who prescribemedications to treat Attention Deficit Hyperactivity Disorder(ADHD). Data presented on Tuesday at the 160th Annual...

ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents

Study highlights importance of antiplatelet therapy compliance NATICK, Mass. and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced results from an analysis of more than 7,000 patients fromits ARRIVE 1 and 2 registries, designed to assess the performanceof the TAXUS(R) Express2(TM) paclitaxel- eluting coronary stentsystem in "real-world" p...

Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial

WASHINGTON, May 22, 2007 /PRNewswire/ -- Results from analyseslooking at factors contributing to successful treatment ofulcerative colitis (UC), were presented at Digestive Disease Week(DDW) this week. Both of these studies were funded by Procter &Gamble (P&G) Pharmaceuticals, Inc. Findings from one studyoffer new information on improvement of quality of life for UCpatients t...